Logo image of WAVE.CA

WAVERLEY PHARMA INC (WAVE.CA) Stock Price, Quote, News and Overview

TSX-V:WAVE - TSX Venture Exchange - CA94357L1058 - Common Stock - Currency: CAD

0.015  -0.01 (-25%)

WAVE.CA Quote, Performance and Key Statistics

WAVERLEY PHARMA INC

TSX-V:WAVE (6/9/2025, 7:00:00 PM)

0.015

-0.01 (-25%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High0.04
52 Week Low0.01
Market Cap810.00K
Shares54.00M
Float13.56M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-25 2025-08-25
IPO04-27 2017-04-27


WAVE.CA short term performance overview.The bars show the price performance of WAVE.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40

WAVE.CA long term performance overview.The bars show the price performance of WAVE.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of WAVE.CA is 0.015 CAD. In the past month the price increased by 50%. In the past year, price decreased by -57.14%.

WAVERLEY PHARMA INC / WAVE Daily stock chart

WAVE.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
FRX.CA FENNEC PHARMACEUTICALS INC N/A 297.19M
EDT.CA SPECTRAL MEDICAL INC N/A 250.91M
EPRX.CA EUPRAXIA PHARMACEUTICALS INC N/A 191.80M
TH.CA THERATECHNOLOGIES INC N/A 156.33M
ONC.CA ONCOLYTICS BIOTECH INC N/A 72.83M
MDNA.CA MEDICENNA THERAPEUTICS CORP N/A 70.40M
COV.CA COVALON TECHNOLOGIES LTD 17.92 63.89M
BLU.CA BLUENERGIES LTD N/A 59.60M
MSCL.CA SATELLOS BIOSCIENCE INC N/A 54.18M
HBP.CA HELIX BIOPHARMA CORP N/A 49.31M
SVA.CA SERNOVA BIOTHERAPEUTICS INC N/A 43.27M
MBX.CA MICROBIX BIOSYSTEMS INC 30.5 42.94M

About WAVE.CA

Company Profile

WAVE logo image Waverley Pharma, Inc. is a pharmaceutical company, which engages in the commercialization and development of oncology drugs. The company is headquartered in Winnipeg, Manitoba. The company went IPO on 2017-04-27. Its primary focus is the PARP-1 program and secondary focus is the generic oncology injectable market in European Union, the United Kingdom (UK) and North America. The company has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted it an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.

Company Info

WAVERLEY PHARMA INC

4-1250 Waverley Street

Winnipeg MANITOBA R3T 6C6 CA

CEO: Larry Thiessen

Employees: 0

WAVE Company Website

WAVE Investor Relations

Phone: 12049287907

WAVERLEY PHARMA INC / WAVE.CA FAQ

What is the stock price of WAVERLEY PHARMA INC today?

The current stock price of WAVE.CA is 0.015 CAD. The price decreased by -25% in the last trading session.


What is the ticker symbol for WAVERLEY PHARMA INC stock?

The exchange symbol of WAVERLEY PHARMA INC is WAVE and it is listed on the TSX Venture Exchange exchange.


On which exchange is WAVE.CA stock listed?

WAVE.CA stock is listed on the TSX Venture Exchange exchange.


What is WAVERLEY PHARMA INC worth?

WAVERLEY PHARMA INC (WAVE.CA) has a market capitalization of 810.00K CAD. This makes WAVE.CA a Nano Cap stock.


How many employees does WAVERLEY PHARMA INC have?

WAVERLEY PHARMA INC (WAVE.CA) currently has 0 employees.


What are the support and resistance levels for WAVERLEY PHARMA INC (WAVE.CA) stock?

WAVERLEY PHARMA INC (WAVE.CA) has a support level at 0.01 and a resistance level at 0.02. Check the full technical report for a detailed analysis of WAVE.CA support and resistance levels.


Should I buy WAVERLEY PHARMA INC (WAVE.CA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does WAVERLEY PHARMA INC (WAVE.CA) stock pay dividends?

WAVE.CA does not pay a dividend.


When does WAVERLEY PHARMA INC (WAVE.CA) report earnings?

WAVERLEY PHARMA INC (WAVE.CA) will report earnings on 2025-08-25.


What is the Price/Earnings (PE) ratio of WAVERLEY PHARMA INC (WAVE.CA)?

WAVERLEY PHARMA INC (WAVE.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.02).


WAVE.CA Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to WAVE.CA. When comparing the yearly performance of all stocks, WAVE.CA is a bad performer in the overall market: 90.82% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

WAVE.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to WAVE.CA. Both the profitability and financial health of WAVE.CA have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

WAVE.CA Financial Highlights

Over the last trailing twelve months WAVE.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 57.28% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -46.29%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%95.14%
Sales Q2Q%830.18%
EPS 1Y (TTM)57.28%
Revenue 1Y (TTM)15.36%

WAVE.CA Ownership and Analysts


Ownership
Inst OwnersN/A
Ins Owners74.9%
Short Float %N/A
Short RatioN/A
Analysts
Analysts0
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A